TRUQAP + abiraterone with prednisone is for certain people with metastatic* prostate cancer that is PTEN-deficient

The FIRST AND ONLY targeted combination therapy of its kind

TRUQAP in combination gave patients ~8 more months without their cancer growing or spreading vs abiraterone with prednisone

TRUQAP + abiraterone with prednisone delivered a median of 33.2 months without their cancer growing or spreading vs 25.7 months with abiraterone + prednisone—a difference of 7.5 months. Results may vary.

Radiographic progression-free survival (rPFS) is a measure of how long a treatment keeps cancer from growing or spreading. Median rPFS is the time point at which half the patients have experienced disease progression. Median is the middle number in a group of numbers listed from lowest to highest.

Combination therapy: TRUQAP + abiraterone with prednisone.

See if TRUQAP is right for you 

Discover how TRUQAP in combination can help.

See results with TRUQAP
Is TRUQAP Right for YouIs TRUQAP Right for You
Talk to your doctor about biomarker testingTalk to your doctor about biomarker testing

Talk to your doctor about biomarker testing

TRUQAP works for certain people with metastatic* prostate cancer that is PTEN-deficient.

Learn about metastatic* prostate cancer and biomarker testing

*Metastatic=cancer that has spread to other parts of the body.

MyTRUQAP Support Program 

Enroll to receive helpful resources, emails, and your TRUQAP starter kit.

See how the MyTRUQAP Support Program can help
MyTRUQAP Support ProgramMyTRUQAP Support Program
handdrawn_arrow handdrawn_arrow

GET HELP
WITH TRUQAP

Access financial
resources and
patient support

Financial Resources and Patient Support Financial Resources and Patient Support

mPC=metastatic prostate cancer; PTEN=phosphatase and tensin homolog.

back to top button